Rochester Red Wings celebrates Stroke Awareness Night with RRH
ROCHESTER, N.Y. (WROC) — A stroke survivor will throw the first pitch in honor of the Rochester Red Wings' collaboration with Rochester Regional Health for Stroke Awareness Night.
Joe Crestuk was told by doctors he would likely never walk or have use of the right side of his body after suffering a stroke in the spring of 2024. After treatment with Rochester Regional Health providers, a year later, he is doing much better.
Crestuk's family, friends, and members of his care team, including his surgeon, will also be in attendance at Saturday's game to celebrate the progress he has made. Their presence and support bring attention to the difference that early intervention, rehabilitation, and a strong support system can have for stroke survivors during recovery.
Organizers said Crestuk's journey is 'an inspiration to many, demonstrating that recovery is possible even after a severe stroke.'
The themed night is an evening of awareness and advocacy to conclude May as Stroke Awareness Month, providing the community with resources on risks and prevention for better health outcomes.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Liberty Coach's Blunt Response to Sabrina Ionescu's Behavior During Blowout
Liberty Coach's Blunt Response to Sabrina Ionescu's Behavior During Blowout originally appeared on Athlon Sports. The New York Liberty are sending a message that they're perhaps primed to win their second straight WNBA championship this season. Advertisement On Sunday, they pulverized the Connecticut Sun by a final score of 100-52, and they equaled their league-record of 19 made 3-pointers in a game, and four of them came from Sabrina Ionescu, who scored a team-high 18 points on 6-of-9 overall shooting. Even though the Liberty were flying high in the third quarter, they challenged a foul that was called on Ionescu when Marina Mabrey of the Sun attempted a 3-pointer. They won the challenge, and Ionescu reacted with an exuberant celebration. She explained the challenge and her celebration, and head coach Sandy Brondello immediately had a response. "I was just really in the moment, but I knew I didn't foul her," Ionescu said. "So very thankful for my coaches and entrusting me with the fact that I asked for a challenge because I know I didn't. My ponytail was sideways. She hit me. Obviously, we were up by a lot, so it was a great opportunity for us to challenge and make sure that I can continue to earn Sandy's trust to be able to continue to challenge." Advertisement "She has my trust," Brondello said. New York jumped out to a 31-13 lead at the end of the first quarter, and it never looked back. It had an incredible 29 assists on 33 made field goals, and it held Connecticut to just 31.1% shooting while forcing 21 turnovers, which helped it score 29 fast-break points. Along with the Minnesota Lynx, New York is the only remaining undefeated team in the WNBA. Jun 1, 2025; Brooklyn, New York, USA; New York Liberty guard Sabrina Ionescu (20) drives past Connecticut Sun center Tina Charles (31) during the second half at Barclays Center. Mandatory Credit: John Jones-Imagn Images Mandatory Credit: John Jones-Imagn Images So far this season, Ionescu is averaging 17.8 points, 4.7 assists and 4.7 rebounds a game. The guard seems to be on her way to her fourth straight All-Star game selection and possibly her fourth All-WNBA nod. Advertisement Sunday's contest was the first Commissioner's Cup contest for the Liberty. They will visit the Washington Mystics on Thursday as the in-season tournament continues. Related: Angel Reese Receives Punishment for Actions in Chicago Sky Game This story was originally reported by Athlon Sports on Jun 2, 2025, where it first appeared.
Forbes
27 minutes ago
- Forbes
Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This
A new survey report from the International Foundation of Employee Benefit Plans shows continued reluctance by United States employers to cover glucagon-like peptide-1 drugs for weight loss. Going forward, however, lower net costs may induce better coverage by employers. Makers of GLP-1s for obesity are offering an array of discounts, some to insurers, others directly to patients. The IFEBP first conducted the survey in Oct. 2023 and again in May 2024. In the latest survey released ten days ago, employers revealed that 55% of them provide coverage of GLP-1s for diabetes only, while only 36% provide coverage for both diabetes and weight loss. And of those employers currently offering GLP-1 drug coverage solely for diabetes, just 17% are considering reimbursement of drugs for weight loss. Broadly speaking, the survey responses demonstrate that a large number of employers are still unwilling to reimburse GLP-1s for obesity. The weight loss therapeutics activate the body's receptors for GLP-1 on its own or in combination with GIP. When released by the gut, these natural hormones increase insulin delivery, suppress appetite, slow stomach emptying and increase the feeling of fullness. Perhaps what's driving continued reluctance to cover these products for weight loss is the overall impact that GLP-1s have on employers' pharmacy budgets. GLP-1 drugs used for obesity account for an average of 10.5% of total annual claims in the 2025 survey. In parts of the traditional health plans' market, we observe that some insurers are reconsidering their coverage of GLP-1s. Blue Cross Blue Shield, for example, just announced a reversal in its policy in which some plans offered coverage of GLP-1s for obesity. Starting in January 2026, BCBS will no longer cover these medicines for weight loss across the insurer's standard plans. At the same time, however, the large insurer Cigna announced it will begin capping out-of-pocket costs at $200 per month, starting next month, for patients using the obesity drugs Wegovy (semaglutide) and Zepbound (tirzepatide) through an add-on to its pharmacy benefit management plans. This is aimed at encouraging more employers to offer coverage of the drugs. It's unknown what the net cost to Cigna will be for the medicines. But presumably, the insurer has been able to reach a deal that's favorable financially, meaning a substantial reduction in net costs. It's possible in future that employers decide to revisit their coverage decisions if net costs decrease sufficiently, combined with more data showing the benefits of weight loss drugs when taken consistently and in conjunction with an appropriate dietary and exercise regimen. Also, the pharmaceutical firm Novo Nordisk announced last month a new partnership with CVS Caremark, the nation's largest pharmacy benefit manager, which grants coverage of Wegovy over its competitor Zepbound for customers who are insured for obesity medications. It's presumed that CVS was able to negotiate sizable rebates for Wegovy. CVS Caremark said that for insured patients, starting this July, Wegovy and Saxenda (liraglutide) will be the preferred GLP-1 medicines on its largest commercial formularies. This implies fewer access restrictions such as prior authorization, but also lower patient cost-sharing. It's unknown precisely what this means in terms of out-of-pocket costs for patients. But most patients with coverage for obesity drugs have monthly cost-sharing under $100. The arrangements reached by Cigna and CVS could help bring down net prices for employers for popular weight loss medicines. And at the same time, under the Inflation Reduction Act, the federal government is negotiating the prices of the GLP-1s Ozempic (semaglutide) and Wegovy. So-called maximum fair prices will be publicly posted in early 2026. These could reflect even steeper discounts. In addition to what payers are doing, Novo Nordisk is pursuing a direct-to-patient strategy to regain market share it has lost to drug maker Eli Lilly in the lucrative obesity drug market. Here, Novo Nordisk struck a deal in which CVS pharmacy will offer Wegovy for $499 a month for cash-paying customers who aren't insured for the medication. Since the Food and Drug Administration removed the active ingredients semaglutide and tirzepatide from its shortage list, the business model of selling directly at a considerable discount to the consumer has become popular for the two main manufacturers of obesity drugs. In 2024, Eli Lilly adopted a direct-to-consumer strategy for Zepbound, among other products, with its LillyDirect program. This service includes a DTC pharmacy and a referral network of in-person and telehealth clinicians. LillyDirect allows uninsured or underinsured individuals not on Medicaid or Medicare to purchase Zepbound product directly after obtaining the requisite prescription from their doctor. The firm recently extended the range of Zepbound products available through LillyDirect by adding high-dose vials at $499. Rival Novo Nordisk also launched a DTC option, NovoCare Pharmacy, two months ago. Patients not insured in the public sector who wish to have access to Wegovy can acquire the drug for an out-of-pocket cost of $499 per month, provided they have a prescription and make use of a designated specialty pharmacy. And, since the end of April, customers also pay a $499 monthly subscription when they obtain Wegovy from Ro and LifeMD, and $599 at Hims & Hers. While employers aren't yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future coverage decisions.
E&E News
28 minutes ago
- E&E News
Meet the youth challenging Trump on climate
Eva Lighthiser, 19, lives in Livingston, Montana, and is accustomed to milelong coal trains rumbling through town and blowing coal dust across the city. In 2023, she was a plaintiff in a youth-led lawsuit that sought to force her state to tackle climate change. Now, she's the lead challenger in Lighthiser v. Trump, a new climate lawsuit that accuses President Donald Trump of violating the Constitution by issuing a trio of executive orders that fast track fossil fuel development. 'Every place is going to be affected by this administration and it's very concerning to see what that will look like moving forward,' Lighthiser said in an interview. Advertisement The case, filed last week in the U.S. District Court for the District of Montana, argues that Trump's executive orders will worsen climate change and increase health dangers by declaring a 'national energy emergency' and directing the government to 'unleash American energy.'
